| Business Summary | | Nexell
Therapeutics
Inc.
is
a
biotechnology
company
whose
principal
subsidiary,
Nexell
of
California,
Inc.
(NCI),
is
developing
products
utilizing
cell
selection
technology
in
cell
therapy
for
cancer
and
other
life-threatening
diseases.
NCI
is
a
leader
in
cell
selection
technology
and
currently
sells
cell
selection
products
in
Europe,
the
United
States
and
Canada.
The
Company
previously
operated
two
other
biotechnology
subsidiaries
engaged
in
the
discovery
and
development
of
biopharmaceuticals,
Innovir
Laboratories,
Inc.
and
Vimrx
Genomics,
Inc.,
both
of
which
have
ceased
operations. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Nexell
Therapeutics
is
biopharmaceutical
company
developing
products
utilizing
cell
separation
technology
in
cell
therapy
for
cancer
and
other
life-threatening
diseases.
For
the
six
months
ended
6/30/01,
revenue
rose
4%
to
$9.8
million.
Net
loss
applicable
to
Common
fell
26%
to
$14.1
million.
Revenues
reflect
increased
sales
of
raw
materials
to
a
manufacturer.
Loss
also
benefited
from
more
focused
research
and
development
efforts
and
lower
personnel
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Richard Dunning, 54 Chairman | $259K | William Albright, Jr., 42 Pres,
CEO, Director | -- | William Wong, Ph.D., 51 Exec.
VP, Bus. Devel. | 188K | David Hirsch, 46 VP
of Global Sales and Marketing | -- | Amy Ross, Ph.D., 46 VP,
Scientific Operations and VP, Diagnostics, NCI | -- | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|